Follow-up to evaluate the the immunogenicity and safety of GSK Biologicals' MMRV [MMR-varicella zoster virus vaccine] vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals' Priorix [Measles mumps and rubella virus vaccine] and Varilrix [varicella zoster virus vaccine live]
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2016
At a glance
- Drugs Measles mumps and rubella virus vaccine; MMR-varicella zoster virus vaccine; Varicella zoster virus vaccine live
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 05 Feb 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 14 Dec 2006 New trial record.